FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine, namely to peptide preparations for treating prostate diseases. The pharmaceutical composition (the first version) comprises 7-60 wt % of a bioregulatory peptide complex of bovine prostate containing water-soluble peptides 9 % more, and 40-93 wt % of a chelate zinc-arginine-glycin complex. The pharmaceutical composition in the form of suppositories (the second version) contains 0.015-0.130 g of the bioregulatory peptide complex of bovine prostate and 0.086-0.200 g of the chelate zinc-arginine-glycin complex as a bioactive compound in one fat-based suppository 2.7-2.9 g.
EFFECT: higher efficacy of the preparation, wider spectrum of its therapeutic action and minimised side effects.
3 cl, 5 ex, 3 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION FOR TREATING DISEASES OF LOWER PART OF GENITOURINARY SYSTEM | 2010 |
|
RU2428173C1 |
| PREPARATION FOR TREATMENT OF PROSTATIC GLAND DISEASES MADE IN FORM OF A SUPPOSITORY | 2019 |
|
RU2752588C2 |
| MEANS FOR TREATMENT OF CHRONIC PROSTATITIS | 2007 |
|
RU2342940C1 |
| AGENT "VITAPROST" FOR PROSTATE GLAND DISEASE TREATMENT | 1996 |
|
RU2112504C1 |
| RECTAL MEDICINAL AGENT FOR CORRECTION OF SPERMATOGENESIS DISORDERS IN MALE INFERTILITY | 2017 |
|
RU2686334C2 |
| RECTAL MEANS FOR TREATING CHRONIC PROSTATITIS | 1999 |
|
RU2160114C1 |
| METHOD FOR TREATING PROSTATIC DISEASES | 2005 |
|
RU2304979C2 |
| RECTAL SUPPOSITORIES FOR PROSTATE TREATMENT CONTAINING LYSYL-GLUTAMYL-ASPARTYL-PROLINE TETRAPEPTIDE | 2017 |
|
RU2640931C1 |
| AGENT FOR TREATMENT OF PROSTATE DISEASE | 2005 |
|
RU2278681C1 |
| RECTAL AGENT | 1999 |
|
RU2152204C1 |
